Mr. Brooks is Co-Chair of the Firm’s whistleblower practice and has been counsel in False Claims Act matters that have returned hundreds of millions in taxpayer dollars to the government.
Ross is a superb lawyer with complete mastery of False Claims Act Litigation. He is my go to for any such matter, and his firm and his own win record and reputation with the Justice Department as well as the percentages recovered for his clients are superior. The prosecutors greatly admire the level of detail and evidence in his submissions, key to a great intervention rate and high recovery to the client. Defendants want to settle, because Ross and his team litigate and win cases turned down by the U.S. Attorney. Also, very nice person who makes an excellent impression on high powered attorneys and clients to whom I introduce him. — Employment Lawyer Charles Joseph of Joseph & Kirschenbaum LLP
Ross’ intelligence, conscientiousness and attention to detail have been critical to the survival and progress of our case in the face of our adversary’s massive resources. — Dr. David Langton, whistleblower client
When it comes to qui tam it would be hard to find a more dedicated team than the one led by Ross Brooks at Sanford Heisler Sharp. They worked tirelessly to ensure my claim was filed swiftly and effectively. It was clear in his interactions with the justice department that Ross Brooks was well respected, experienced, and had a good working relationship with them. Years later, I remain in contact with both David Sanford and Ross Brooks, and continue to appreciate their consistent efforts to exceed all professional expectations. I highly recommend Ross Brooks and the Sanford Heisler Sharp qui tam team. — Angie Silva, Whistleblower client
Ross has taken me through a journey of difficult legal issues, and has a great ability to foresee events and pursue a wise course of action. — Dr. Tony Nargol, whistleblower client
I want to congratulate my friend and fellow whistleblower lawyer Ross Brooks for some great work he did in a suit that tried to stop some really callous treatment of schoolchildren – special education kids, at that. — Whistleblower Attorney Lee Wallace of The Wallace Law Firm, L.L.C.
Ross Brooks is a Partner in the New York office of Sanford Heisler Sharp, LLP, a national law firm with offices in Washington, DC, New York, California, Tennessee, and Maryland. He received his law degree from The University of Chicago Law School in 1997.
Mr. Brooks is Co-Chair of Sanford Heisler Sharp, LLP’s whistleblower practice. He has been counsel in whistleblower matters that have returned hundreds of millions in taxpayer dollars to the Government. Mr. Brooks represents whistleblowers in actions brought under the False Claims Act, The Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank), and other whistleblower statutes. He has represented whistleblowers in False Claims Act (Qui Tam) matters to recover funds defrauded from the Medicare and Medicaid programs, the Department of Veterans Affairs (VA), the Department of Defense (DoD), the Title IV Student Loan Program, the Department of Housing and Urban Development (HUD) and other government payers.
Mr. Brooks currently represents whistleblowers in numerous sealed Qui Tam actions under investigation by the United States and other governmental stakeholders. Mr. Brooks also represents whistleblowers in active litigation, including in the unsealed, non-intervened litigations United States et al. ex rel. Nargol and Langton v. DePuy Orthopaedics, et al. (alleging unlawful sales of ineffective and unsafe hip replacement medical devices to government health insurance programs); United States ex rel Derrick v. Roche Diagnostics et al (alleging unlawful kickbacks paid to secure favorable Medicare Advantage formulary placement); and United States ex rel Raffington v. Bon Secours (alleging unlawful billing fraud by home healthcare company).
Mr. Brooks’ past False Claims Act recoveries have included United States ex rel. Silva v. Amgen ($762 million intervened settlement of claims against pharmaceutical manufacturer arising from unlawful marketing and kickbacks paid to physicians to induce purchases of anemia drugs); United States ex rel. Gale v. Omnicare ($116 million non-intervened settlement of claims against long-term care pharmacy arising from unlawful kickbacks paid to nursing homes to induce drug purchases); United States ex rel. Cox v. Smith & Nephew ($11.3 million non-intervened settlement arising from unlawful sales of medical devices under government contracts requiring compliance with the Trade Agreements Act); United States ex rel. Simmons v. Meridian, ($5.1 million non-intervened settlement arising from unlawful kickbacks paid by ambulatory surgical center (ASC) owners to physicians to induce referrals of patients to ASCs); United States ex rel. Cox v. Medtronic, Inc. (more than $4.4 million intervened settlement arising from unlawful sales of medical devices under government contracts requiring compliance with the Trade Agreements Act); United States ex rel Gipson v. Pathway Genomics (more than $4.1 million intervened settlement arising from unlawful kickbacks paid to physicians to induce government purchases of genetic tests); United States ex rel Forrest v. Scripps ($1.5 million intervened settlement arising from unlawful billing practices for outpatient physical therapy services); United States ex rel. Ohlmeyer v. City of New York ($1.4 million intervened settlement of claims against the City of New York arising from failures to provide adequate psychological counseling to public school special education students); Mason v. Medline ($85 million non-intervened settlement arising from medical supplies manufacturer’s unlawful kickbacks paid to hospitals to induce purchases of medical supplies); and United States ex rel. Marchese v. Cell Therapeutics, Inc. ($10.5 million intervened settlement against pharmaceutical manufacturer arising from unlawful marketing to induce purchases of cancer drugs).
Mr. Brooks also represents governmental entities, labor unions, and individuals in consumer fraud class actions and other civil litigation and healthcare cost recovery efforts. Mr. Brooks has served as outside counsel to governmental entities, including Nassau County in New York in In re Pharmaceutical Industry Average Wholesale Price Litigation ($275 million settlement in consolidated action alleging that over 40 drug manufacturers engaged in unlawful pharmaceutical drug pricing fraud that cost dozens of New York Counties millions of dollars in Medicaid expenditures). Brooks has represented labor unions and individual consumers in the consumer fraud class actions In Re Vytorin/Zetia Marketing, Sales Practices and Products Liability Litig., ($41.5 million settlement arising from fraudulent marketing of anti-cholesterol drugs to consumers) and In re Hydroxycut Marketing and Sales Practices Litigation ($25.3 million settlement arising from the fraudulent marketing of dietary supplements to consumers). Brooks represented investors in the securities fraud class actions In re Nortel Networks Corp. Securities Litigation ($1.1 billion settlement); In re Sears, Roebuck & Co. Securities Litigation ($215 million settlement); and In re Gilead Sciences Securities Litigation ($8 million settlement).
Brooks began his career working in the defense bar on behalf of Fortune 500 companies in complex commercial litigation. He performs regularly as a jazz guitarist in the New York metropolitan area and serves on the Advisory Board of the Musicians Aid Society of New York (MASNY).
- J.D., University of Chicago Law School, 1997
- B.A., Cornell University 1992, cum laude
- Mandel Legal Aid Clinic
- New York 1999
- U.S. District Court for the Southern District of New York 1999
- U.S. District Court for the Eastern District of New York 2010
- R. Brooks and I. Hemani, "Private Insurance Qui Tam Laws Expand Kickback Liability and Available Remedies to Private Insurers," Pharmaceutical Comliance Monitor (2016).
- R. Brooks and I. Hemani, “Proposed CMS Rule Increases OIG and FCA Focus on the Medicare Part D Prescription Drug Benefit,” Pharmaceutical Compliance Monitor (2014).
Galax and Giles County filed the lawsuits in state court against more than 15 opioid manufacturers, distributors, and PBMs — including pharmaceutical titan Purdue Pharma and worldwide distributor McKesson.
Page County filed the lawsuit in state court against more than 15 opioid manufacturers, distributors, and PBMs — including pharmaceutical titan Purdue Pharma and worldwide distributor McKesson.
Martinsville and Henry County filed the lawsuit in state court against more than 15 opioid manufacturers, distributors, and PBMs — including pharmaceutical titan Purdue Pharma and worldwide distributor McKesson.
Lee County and the City of Norton filed the lawsuit in state court against more than 15 opioid manufacturers, distributors, and PBMs — including pharmaceutical titan Purdue Pharma and worldwide distributor McKesson.
Montgomery County filed the lawsuit in state court against more than 15 opioid manufacturers, distributors, and PBMs — including pharmaceutical titan Purdue Pharma and worldwide distributor McKesson.
Sanford Heisler Sharp, LLP brought whistleblower claims on behalf of Dr. Antoni Nargol and Dr. David Langton, two physicians and researchers who were first to uncover that medical-device company DePuy Orthopaedics manufactured and sold large numbers of defective hip implants to the government.
The whistleblower alleged that the San Diego-based Scripps Health System unlawfully billed the United States Government for physical therapy services on behalf of a physician who was not present while the services were rendered. The case claimed that Scripps persisted in this conduct despite warnings from the whistleblower.
The City of Alexandria and Dickenson County, Virginia, represented by Sanford Heisler Sharp, LLP, and The Cicala Law Firm PLLC became the first municipalities in the Commonwealth of Virginia to pursue legal action against opioid manufacturers, distributors, and pharmacy benefit managers (PBMs) for their role in creating the public health emergency caused by prescription opioids.
The Relator’s Complaint alleges that in 2013, Roche paid Humana a kickback in exchange for Humana placing Roche’s diabetes testing products on its Medicare Advantage formularies.
The case is thought to be the first in New York to recover money for the United States government based on the defendant’s failure to properly mark its products with their country of origin.
- Bon Secours Health System Wants Claims In FCA Suit Tossed
- Health Plans Facing More Kickback Risk
- Humana, Roche Diagnostics Face $45M Federal Kickback Lawsuit
- Sanford Heisler Sharp’s False Claims Act Action Against Medicare Advantage Organization Moves Forward — Court Denies Defendants’ Motions to Dismiss
- Alexandria and Dickenson County First in Virginia to Take Legal Action Against the Opioid Industry
- J&J Unit Can’t Nix FCA Suit Over Hip Implants Yet
- Appeals Court Revives FCA Case Over Faulty Hip Implants
- J&J, DePuy To Face Partly Revived FCA Suit Over Hip Device
- Bon Secours Must Face Ex-Employee’s FCA Suit
- Genzyme Seprafilm Admissions Muted In New DOJ Settlement
Recent DOJ Settlement of Qui Tam and Antitrust Claims in Bid-Rigging Case Shows That an Additional Remedy Does Not Have to Be an Alternate Remedy
The False Claims Act (“FCA”) incentivizes whistleblowers (“relators”) to provide information to the Government that could lead to a recovery of defrauded taxpayer funds, with a share of that recovery going to the whistleblower. But sometimes a relator’s information can lead the Government to pursue claims only on its own behalf, for which there is […]
If you are aware of a False Claims Act violation that occurred more than six years ago and are concerned that it may be too late to file a claim, you should give us a call. Whistleblowers generally have no more than six years to preserve their right to pursue a False Claims Act case […]